ESMO Gastrointestinal Oncology

OCT 21, 2026 · JOURNAL ARTICLE

Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first-line therapy

ESMO Gastrointestinal Oncology

Background Treatment options for refractory gastric cancer are limited. Preclinical data suggest interplay between angiogenesis and immune regulation, with vascular endothelial gro

OCT 17, 2026 · JOURNAL ARTICLE

Beyond PD-L1 and HER2: emerging predictive biomarkers in gastroesophageal tumors

ESMO Gastrointestinal Oncology

Gastroesophageal adenocarcinoma (GEA) remains a major cause of cancer morbidity and mortality, with substantial geographic variation and marked inter- and intratumoral heterogeneit

SEP 17, 2026 · JOURNAL ARTICLE

Care delivery among patients with early-onset versus average-onset cholangiocarcinoma: a nationwide retrospective analysis

ESMO Gastrointestinal Oncology

Background Cholangiocarcinoma (CCA) is an aggressive biliary malignancy with increasing incidence and poor prognosis. Although traditionally considered a disease of older adults, e

SEP 15, 2026 · JOURNAL ARTICLE

Patterns of presentation and diagnostic delays in biliary tract cancers: a real-world European study

ESMO Gastrointestinal Oncology

Background Biliary tract cancers (BTCs) often present late due to nonspecific symptoms and a lack of effective population screening. We characterised diagnostic routes, symptom-to-

SEP 10, 2026 · REVIEW

Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis

ESMO Gastrointestinal Oncology

Rigorous meta-analysis of 25 studies with adequate pooled sample sizes quantifies clinically meaningful spatial heterogeneity in Claudin-18.2 expression, with clear implications for specimen selection in targeted therapy decisions.

AUG 17, 2026 · JOURNAL ARTICLE

Management of nausea and vomiting with claudin 18.2-targeted therapy in upper gastrointestinal cancer

ESMO Gastrointestinal Oncology

This is an expert panel discussion on practical management of adverse effects from a specific therapy, not a study reporting original evidence on efficacy or safety.